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Abstract
Background: Three-dimensional (3-D) cultures of cancer cells can potentially bridge the gap between 2-D drug
screening and in vivo xenografts. The objective of this study was to characterize the cellular and extracellular matrix
characteristics of spheroids composed of human lung epithelial cells (epi), pulmonary vascular endothelial (endo)
cells, and human marrow-derived mesenchymal stems cells (MSCs).
Methods: Spheroids composed of epi/endo/MSCs, termed herein as synthetic tumor microenvironment mimics
(STEMs), were prepared by the hanging drop method. Cellular composition and distribution in the STEMs was
characterized using fluorescence microscopy. Induction of reactive oxygen species and upregulation of efflux
transporters was quantified using fluorometry and PCR, respectively, and phenotypic markers were qualitatively
assessed using immunohistochemistry.
Results: STEMs exhibited three unique characteristics not captured in other spheroid cultures namely, the presence
of a spheroid core devoid of epithelial cells and primarily composed of MSCs, a small viable population of
endothelial cells hypothesized to be closely associated with MSCs within the hypoxic core, and discrete regions
with high expression for vimentin and cytokeratin-18, whose co-expression is co-related with enhanced metastasis.
Although cells within STEMs show elevated levels of reactive oxygen species and mRNA for ABC-B1, an efflux
transporter associated with drug resistance, they exhibited only modest resistance to paclitaxel and gemcitabine in
comparison to 2-D tri-cultures.
Conclusions: The epi/endo/MSC spheroid model described herein offers a promising platform for understanding
tumor biology and drug testing in vitro.
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Background
Cancer is a multifactorial and dynamic disease that con-
tinues to be a challenge to treat [1]. The development of
effective tumor therapeutics significantly depends on re-
liable in vitro screening systems. The absence of reliable
in vitro screening models that could recapitulate key as-
pects of tumor microenvironment such as drug resistance
and phenotypic changes to cells is an impediment to the
reliable translation of in vitro findings into in vivo clinical
models. This poor in vitro-in vivo correlation is one factor
that has an adverse impact on drug development costs,
which are currently projected to exceed $1.5 billion for
each single drug that gains approval [2]. Therefore,
there is a need to develop in vitro models that can
more accurately reflect the in vivo environment and in
vivo efficacy. Towards this long-term objective, 3-D ag-
gregates of tumor cells, commonly referred to as tumor
spheroids, are an attractive alternative to 2-D cell cul-
ture [3] as they can reproduce many aspects of the
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tumor microenvironment including paracrine effects,
cell-cell interactions, and extracellular matrix deposition
[4–6]. Furthermore, 3-D cell culture can recapitulate
many of the environmental factors that induce metabolic
and oxidative stress in cells within tumors, such as oxygen
and nutritional gradients, hypoxia, and the formation of a
necrotic core [3]. 3-D spheroids additionally have the po-
tential to reduce the time and costs associated with trans-
lation of laboratory findings into animal models, [7]
and are also compatible with the next generation high
throughput screening technologies [8, 9].
It is well established that tumors are heterogeneous in
both cellularity (epithelial, vascular, immune cells, and fi-
broblasts) and extracellular matrix (ECM) composition
[1]. Multicellular tumor spheroid models currently de-
scribed in the literature are typically generated using ei-
ther the primary cells from tumor explants or tumor cell
lines, and in some instances are co-cultured with fibro-
blasts or endothelial cells [3, 10, 11]; therefore placing
greater emphasis on the interaction between epithelial
cells and stromal cells. In this context a tri culture sys-
tem composed of human breast cancer epithelial cells,
fibroblasts and endothelial cells has been described for
high-throughput screening [12]. However, the stroma of
a solid tumor has in addition to vascular cells and im-
mune cells, tumor-associated fibroblasts, which are be-
lieved to be derived from mesenchymal stem cells
(MSCs) [13]. There is also evidence that MSCs may
serve as precursor to the stromal cells in epithelial tu-
mors [14]. MSCs, in addition to acting as support cells
provide physical cues and soluble cues for angiogenesis
[15], are also assumed to have an immunomodulatory
role and help in driving an aggressive and drug resistant
tumor phenotype [16, 17]. It has been shown that MSCs
are actively recruited by tumors to aid in their growth
and formation and it has been postulated that MSCs
have the capacity to aid in the formation of the cancer
niche [18], and their recruitment facilitates metastasis in
prostate tumors [19]. For example, the co-injection of
MSCs with melanoma cells has been demonstrated to
promote allogeneic tumor formation by suppressing the
host immune response [20]. These observations prompted
us to characterize spheroids derived from lung epithelial
adenocarcinoma cells (A549) when co-cultured with hu-
man MSCs and human pulmonary microvascular endo-
thelial cells (HPMEC). The rationale to include endothelial
cells in the spheroid formation was to test the hypothesis
that MSCs additionally might play a role in sustaining
endothelial cells in the harsh nutrition depleted environ-
ment of tumor cores. To the best of our knowledge this is
the first study to characterize multicellular spheroids of
epithelial, MSCs, and endothelial cells. This multicellular
spheroid system, which we have termed synthetic tumor
Microenvironment mimics (STEMs), exhibits many traits
of mature tumor environments including a necrotic core
devoid of epithelial cells, induction of drug resistance
markers, and resistance to chemotherapeutics.
Methods
Cell culture experiments
The A549 cell line was provided by the BIOSS toolbox
(Centre for Biological Signalling Studies, University of
Freiburg) and was genotyped and verified by Labor für
DNA Analytik (Freiburg, Germany). A549 was cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM) sup-
plemented with 10 % fetal bovine serum (FBS) (Life
Technologies, Germany), and 100 U/mL penicillin-
streptomycin (PAN Biotech, Germany). The cells were
cultured to 70–80 % confluency before being trypsinized
for spheroid formation. Human pulmonary microvascu-
lar endothelial cells (HPMEC) were procured from
ScienCell (USA) and cultured in endothelial cell growth
medium (ScienCell, USA) supplemented with 5 % FBS
and 50 U/mL penicillin-streptomycin. Human marrow-
derived mesenchymal stem cells were kindly provided by
Dr. Andrea Barbero and were obtained from patients
under consent in accordance to the regulations of the in-
stitution’s ethical committee (University Hospital Basel;
Ref Number of local ethical committee: 78/07). MSCs
were sub-cultured in alpha-MEM containing 10 % FBS,
1 % penicillin-streptomycin, and 5 ng/ml fibroblast growth
factor-2 (FGF2). HEK293 cells (a cell line derived from
Human embryonic kidney cells) were obtained from
BIOSS Toolbox (University of Freiburg, Germany),
were genotyped and verified by Labor für DNA Analy-
tik (Freiburg, Germany). They were sub-cultured in
DMEM with 10 % FBS.
Transduction of A549 cells and HPMECs
Preparation of the viral particles
Lentiviral particles were produced in HEK293 cells.
HEK293 cells (1x106 cells/well) were seeded in a 6-well
plate and allowed to attach overnight, and then incu-
bated with the lentiviral vector and packing vectors in
presence of polyethyleneimine (PEI, MW 25Kda, Sigma,
Germany) as the transfection agent. 5 μg of DNA (4:3:1
of transfer vector (GFP: pGIPZ (Openbiosystems, RHS4
346), RFP: pTRIPZ RFP ires Not1 (BIOSS Toolbox, Uni-
versity of FReiburg)), packaging coding vector (pCMV-
dR8.74, Addgene, Plasmid #22036)) and envelope coding
vector (pMD2.G, Addgene, Plasmid #12259) were di-
luted in 250 μL Opti-MEM (Invitrogen, Germany) and
11.25 μl of PEI was mixed rapidly and incubated for
10 min and then added to the HEK293 cells. After 16 h,
the cell medium was replaced with 2 ml of fresh
medium. The following day, the culture medium was re-
placed with complete medium based on the target cells
(DMEM or ECM) and 36 h after transfection, the
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medium containing viral particles was harvested and fil-
tered using a 0.2-μm filter, and then stored at −80° Cel-
sius until further use.
Transduction of A549 and HPMEC
A549 or HPMEC were were seeded at a density of 7x104
cells/well in a six well plate, and the cells were allowed
to attach overnight, and on the following day the
medium was changed and the viral particles encoding
for the fluorescent protein of interest were added (RFP
transduction of A549: 2 ml of viral particles; GFP trans-
duction of HPMEC: 100 μl of viral particles). This step
was repeated the following day to ensure robust trans-
duction. After 24 h, 4 μg/ml of puromycin was added to
select the transduced cells, and the dead cells were re-
moved during medium change.
Preparation of STEMs
Spheroids were prepared using the hanging drop method
(Fig. 1a). When the cell cultures reached 70–80 % con-
fluency, cells were harvested by trypsinization, and STEM
formation was initiated by combining A549, HPMEC, and
MSCs at a ratio of 5:3:2 at a total density of 25×103 cells/
25 μl/well in a 96 well hanging drop plate (3-D Biomatrix,
USA). The choice of the cell ratio was based on the obser-
vation that stromal cells in general comprise a smaller
fraction of the tumor, and recent studies have shown that
at an A549: MSC ratio of 3:1, MSCs exert a proliferative
effect on A549 in vivo [21]. Furthermore, it is has been
shown that increased vascularity along the periphery of
non-small cell lung carcinoma, of which adenocarcinoma
is a subtype, is associated with tumor progression [22].
Therefore, we chose to have a starting cell composition
that was high in HPMECs. The wells of the plate were
filled with 4 ml of PBS to ensure that there was no evapor-
ation of the cell culture medium from the drop. The
medium in the drop was changed every alternate day by
removing 2.5 μl of medium from the culture and adding
5 μl of fresh media to the wells.
Characterization of temporal changes to the cell
composition in STEMs
In order to determine the temporal changes in cell
population within the STEMs, STEMs were prepared
using RFP and GFP expressing A549 and HPMEC re-
spectively, and at pre-determined time points the spher-
oids were dissociated and the cell population quantified
using flow cytometry. Spheroids were collected on day 1,
i.e., 24 h after start of the experiment, day 3, 6, 10, and
15, and then transferred into an Eppendorf tube (4
spheroids per tube, n =3) and treated with collagenase
(0.3 % Sigma Aldrich, Germany) for 30 min, and kept on
a shaker maintained at 37 °C. The dissociated cells were
resuspended with 300 μl of fluorescence-activated cell
sorting (FACS) buffer and stored on ice until the FACS
analysis was performed. For each of the experimental con-
ditions, 10,000 viable cells were counted using a Gallios
flow cytometer (Beckman Coulter, USA) and the viable
cell population was analyzed using Kaluza software (ver-
sion 1.2, Beckman Coulter) to determine the cellular
composition. Percentage of cells that were RFP positive
corresponded to A549 population, percentage of cells
that were GFP positive corresponded to HPMEC popu-
lation, and cells that were negative for both GFP and
RFP corresponded to the MSC population.
Fluorescent microscopy of STEMs
STEMs produced using fluorescent protein expressing
cells were harvested on day 15 by placing a few drops of
PBS through the wells, fixed with 3.7 % formaldehyde
and then embedded in OCT (VWR, Germany) over-
night. The STEM spheroids were then sectioned into
10 μm sections using a cryo-stat (HYRAX C20, Zeiss),
transferred onto slides (Superfrost, VWR, Germany),
stained with DAPI nuclear stain, and then imaged using
a Zeiss Cell Observer Z1 (Carl Zeiss, Germany) fluores-
cent microscope. Imaging of spheroids after live/dead
staining images were acquired using a Zeiss LSM 510
confocal miscrocope.
Scanning electron microscopy of STEMs
To investigate the organization of cells within the
STEMs as a function of time, spheroids were harvested
on day 3, 6, 10, and 15, fixed with 2.5 % glutaraldehyde,
dehydrated using graded series of ethanol, and dried in a
vacuum desiccator at room temperature for 2 h. The
desiccated spheroids were then sputter coated with gold
for 60 s before imaging using a scanning electron micro-
scope (SEM) (FEI Quanta 250 FEG). The images were
acquired at an accelerating voltage of 20 KV and cham-
ber pressure of 1.14 × 10 Pa at three different magnifica-
tions: 400 X, 6000 X, and 12000 X.
Metabolic acitivty of cells within STEMs
Metabolic activity in STEMs was examined using a 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium brom-
ide (MTT) assay. In the MTT assay, the MTT dye is
converted by cellular mitochondrial esterases into an in-
soluble purple colored formazan that is measured spec-
trophotometrically and is reflective of metabolic activity
of the cell [23]. Spheroids were harvested at day 3, 6, 10,
and 15, and incubated with 0.5 mg/ ml of MTT for 3 h .
Following this, the MTT solution was aspirated and
100 μl of dimethyl sulfoxide was added to dissolve the
purple colored formazan crystals. Absorbance was mea-
sured at 550 nm using a Synergy HT microplate reader
(Bio-TEK Instruments INC, USA) (n = 3).
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Quantification of cell viability within STEMs
The fraction of viable cells within the STEMs was assessed
using two quantitative methods: trypan blue exclusion
after spheroid dissociation and FACS analysis.
Trypan blue exclusion assay
Spheroids were harvested on day 3, 6, 10, and 15, and
trypsinized; and the cell suspension was diluted 1:1 with
Trypan blue solution (0.4 w/v %), and counted using a
hemocytometer (n = 3 spheroids with 3 technical re-
peats). In this assay, live cells exclude the dye and re-
main unstained while dead cells are stained blue.
FACS analysis
The fraction of viable cells within the population of cells
that were analyzed was use to determine the fraction of
non-viable cells.
Visualization of live and dead cells within STEMs
Following 15 days of culture, the spheroids were har-
vested from the hanging drop plate by pipetting 100 μl
of PBS through the wells containing spheroids into
1.5 ml microcentrifuge tubes. The spheroids were then
washed with PBS and were stained using the live/dead
staining kit (Life Technologies, Invitrogen, Germany) by
incubating with 6.25 μl each of calcein AM (1:400) and
ethidium homodimer (EthD-1) (1:100) at 37 °C for
30 min to visualize live and dead cells and regions of cell
death. The spheroids were then imaged with a confocal
microscope (Carl Zeiss, Germany) (n = 3).
Oxidative stress assessment in STEMs
Reactive oxygen species (ROS) generation in STEMs was
compared to cells grown on 2-D tissue culture polystyr-
ene plates (TCPS). Intracellular ROS was quantified
using a fluorescent assay where the non-fluorescent
dichlorofluorescein diacetate (DCFH-DA) substrate in
the presence of ROS is converted into the fluorescent
dichlorofluorescein (DCF). After 15 days of culture,
spheroids were transferred to flat-bottomed, dark sided
96 well plates, washed with PBS once, and incubated
with 100 μl DCFH-DA for 45 min at 37 °C. Fluorescence
was then measured using a plate reader (Bio-TEK, USA)
at λexcitation 485 nm and λemission 535 nm. Finally, the
ROS values were normalized with respect to cell number
determined by MTT assay (n = 7).
Visualization of hypoxia in STEMs
Spheroids were harvested after 15 days in culture, treated
with 200-μM pimonidazole for 3 h , fixed with 3.7 % for-
maldehyde, and sectioned. Then the sections were perme-
abilized with 0.1 % Triton-X 100, blocked with 2.5 % goat
serum, and incubated with anti-pimonidazole antibody
(1:200) (Hypoxyprobe™ Red 549 kit, Hypoxyprobe, Inc.,
USA) overnight at 4 °C. The samples were then washed
with PBS, stained with DAPI, and imaged using a Carl
Zeiss microscope, Germany. Since pimonidazole does not
bind to necrotic region, the regions of hypoxia can be dis-
tinguished from regions of anoxia [24]. The scoring of re-
gions of proliferation and hypoxia was carried out as
described by Mikhail et al. [25].
Immunohistochemistry
The expression of phenotypic markers was analyzed
qualitatively using immunohistochemistry. The spher-
oids and their corresponding 2-D controls were fixed
with 3.7 % formaldehyde, and in the case of spheroids,
subsequently embedded in OCT before sectioning. The
10 μm thick sections were rehydrated, incubated with
2.5 % goat serum and 0.1 % Triton X-100 in PBS for 1 h.
The samples were then incubated with primary antibody
CK-18 (1:100, Abcam, Clone: E431-1), fibronectin (1:300,
Abcam, Cat No. ab6584), vimentin (1:800, Sigma Aldrich,
Germany, Clone V9), and CD 31 (1:100, Abcam, Cat No.
ab28364). The sections were then washed with PBS,
and incubated with biotinylated secondary antibodies.
Color development was performed using the Vectas-
tain Elite kit and diaminobenzidine (DAKO). The sam-
ples were then counterstained with hematoxylin and
imaged using a Carl Zeiss Z1 Cell observer microscope
(Germany) (n = 3).
Expression of ABC-B1 drug resistant marker in STEMs
Gene expression levels of ATP-binding cassette (ABC)
sub family B member 1 (ABC B1) in STEMs were mea-
sured using real time RT-qPCR at the end of day 15. For
2-D samples, the three cell types were cultured together
and RNA isolation was performed at 60–70 % con-
fluency using RNAeasy mini kit (QIAGEN), followed by
cDNA synthesis by using 250 ng of RNA (Quantitect RT
kit, Qiagen). Expression of ABC-B1 was normalized using
18 s rRNA. The sequence of the primers were as follows:
ABC-B1: Forward: CAGAGGGGATGGTCAGTGTT; Re-
verse: CCTGACTCACCACACCAATG; 18srRNA: For-
ward: CCTGCGGCTTAATTTGACTC; Reverse: AACTA
AGAACGGCCATGCAC (n = 4).
Response of STEMs to paclitaxel and gemcitabine
Sensitivity of STEMs at the end of day 15 to escalation
in paclitaxel dose (1, 10, 100, and 1000 nM) and gemci-
tabine (1, 10, 30, and 100 μM) was studied and com-
pared to 2-D triculture at 60–70 % confluency. 48 h
after exposure to paclitaxel and gemcitabine, the loss in
cell viability was assessed using MTT assay, and the data
represented as percentage change with respect to un-
treated cells (n = 3).
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Statistical analysis
All the quantitative data are expressed as mean value ±
standard deviation. Statistical analysis was carried out
using student’s t-test. A p value of < 0.05 was considered
as statistically significant and * represents p < 0.05, **
represents p < 0.01, and *** represents p < 0.005.
Results and discussion
Characterization of STEMs
Since epithelial tumors are heterogeneous with respect
to their cell population and also comprise mesenchymal
cells, endothelial cell, immune cells, and fibroblasts
[26], in this study we aimed to capture this complex-
ity in vitro using a triculture spheroid system derived
from A549; human lung epithelial cells, human lung
microvascular endothelial cells, HPMEC, and human
bone marrow-derived MSCs. Such a system, in theory,
could recapitulate some of the in vivo tumor traits,
and if so, could provide an interesting platform for
tumor staging experiments and drug screening. Al-
though there are a number of techniques available for
generation of 3-D cellular aggregates [27], we chose
the hanging drop method (Fig. 1a) for generation of
STEMs as it is known to yield spheroids of uniform
size and promote the formation of tissue-like struc-
tures with robust ECM deposition [10]. The spheroids
were then characterized for their cellular organization
and morphology, composition, cell viability, cell
phenotype, stress-related markers, and responsiveness
to paclitaxel and gemcitabine.
Fig. 1 a Schematic representation of synthetic tumor microenvironment mimic (STEM) generation using the hanging drop method, b Scanning
electron micrographs of STEMs at the end of day 3, 6, 10, and 15 (Scale bar 400 X: 200 μm, 6000 X: 10 μm, and 12000 X: 5 μm), c Temporal
changes to the cellular compositon of the STEMs as determined by FACS (n = 3), d Fraction of live and dead cells in the STEMs as function of
time as assessed by fluorescence activated cell sorting experiment (FACS, n = 3), e Percentage of live/dead cells as determined by Trypan blue
staining (** indicates significance (p < 0.01) between day 3 and day 15, and *** indicates sigificance (p < 0.001) between day 6 and day 15; and
day 10 and day 15). Statistical analysis depicts comparison between the dead populations on each day. f Metabolic actitvity (MTT assay) of STEMs
as a function (*** indicates (p < 0.005) between day 10 and day 15)
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Morphological characterization of STEMs using SEM
As stated earlier the ratio of 5:3:2 of epithelial/endothe-
lial/MSC at the start of the spheroid formation was
based on literature observations that adenocarcinomas
are highly vascuralized [22] and MSCs when mixed with
A549 in the ratio 1:3 exert a proliferative effect [21]. As
a first step, a qualitative assessment of the cellular
organization in the STEMs was made using SEM at 3, 6,
10, and 15 days after initial spheroid formation (Fig. 1b).
The choice of time points was based on the fact that
around 15 days reliable measures of tumor microenvir-
onment can be gathered [28] and beyond that period ex-
cessive loss of cell viability due to diffusional and
nutritional limitations would outweigh the benefits of
long-term culture. Furthermore, 15 days was deemed
sufficient for the evolution of tumor-related characteris-
tics such as a hypoxic core, phenotypic markers (CK-18,
fibronectin) and drug resistance markers (ABC-B1) as
discussed later. On Day 3, the cells generally appeared
loosely organized. However, on day 6 a consolidation of
the cells within the spheroids was evident. Beyond day 6,
deposition of ECM was observed (depicted by yellow
arrow) and this pattern of cellular organization and
ECM deposition is consistent with our recent finding
that changes to epithelial tumor volume in vivo initially
is primarily due to ECM deposition and not due to an
increase in cell numbers [29]. This promoted us to in-
vestigate the temporal changes to the cellular compos-
ition of the STEMs as discussed below.
Temporal changes to cellular composition, viability, and
metabolic activity within STEMs
In order to ascertain the changes to the three distinct
cell populations within the STEMs as a function of time,
HPMEC and A549 were transduced using lentivirus to
stably express turbo GFP and turbo RFP, respectively,
and the cellular composition of the STEM was quanti-
fied by FACS as function of time (Fig. 1c). Based on the
cellular population at the initiation of the spheroids of
5:3:2 (A549/HPMEC/MSC), at day 1 it was clear that
much of the ECs had perished, and the cellular compos-
ition of the STEM was tipped towards A549 and MSC
with these two cell populations almost being in equal ra-
tio, and with less than 15 % HPEMCs (A549/HPMEC/
MSC; 4.8/1.4/3.8). Interestingly, between days 1 and 3, a
6-fold downward change in MSC population was ob-
served and a further loss of endothelial cells. Consider-
ing that the overall fraction of viable cells as per FACS
analysis remained relatively unchanged between days 1
and 3 (Fig. 1d) this might allude to a potential prolifera-
tion of the A549 population. However, between days 3
and 10, the dead cell population within the spheroids
showed a significant increase ranging from 20 to 40 %,
as per trypan exclusion analysis of the dissociated
STEMs (Fig. 1e), and FACS analysis (Fig. 1d). The cellu-
lar composition of the STEMs during this period showed
a further significant loss in ECs and the emergence of
the MSC fraction with a concurrent downward trend in
A549 fraction. Interestingly, MTT metabolic assay also
showed higher metabolic activity (Fig. 1f ), which may be
attributed in part to the plausible proliferation of MSCs.
This trend in the changes in the cellular composition
and metabolic acitivty continued between days 6 and 10
with an eventual stabilization of the cellular composition
within the STEM at day 15. At day 15 the STEMs were
composed of an approximately equal fraction of A549
and MSC with an EC fraction of less than 0.1 %. This
was also accompanied by a severe reduction in metabolic
activity within the STEMs (Fig. 1f ). The increase in
MSC population with spheroid growth is an important
aspect of the STEMs as they mimic the emergence of a
stromal population in tumors upon maturation [20].
This upward change in MSC numbers is consistent with
literature reports that hypoxia enhances survival [30]
and proliferation of MSCs [31], a presumption that is
strengthened by the metabolic activity data between days
3 and 6 (Fig. 1f ), which shows an increased metabolic
activity that coincides generally with the increase in MSC
and epithelial cell fraction in the STEMs. Interestingly, the
fraction of the ECs during the STEM development be-
tween day 6 and 15 remained low and relatively constant
at around < 1.0 %; and the significance of this observation
is discussed further in the following sections.
Characterization of cellular microenvironment and cell
distribution in STEMs
One of the characteristics of a solid tumor is the forma-
tion of regions of hypoxia, which in part stems from the
presence of aberrant vasculature [1, 3]. Hypoxia in solid
tumors is known to promote quiescent cell populations,
such as cancer stem cells (CSCs), which alter the re-
sponsiveness of tumors to anticancer drugs and radio-
therapy [32–34]. Hypoxia is prominent notably in the
stromal cell-rich necrotic tumor core, which is believed
to foster the survival of a drug resistant tumor cell popu-
lation that is thought to be responsible for the relapse of
a primary tumor [35]. It is well known that spheroids
in vitro can also possess a hypoxic core, and the STEMs
described herein are no exception. It is evident from the
representative image of a spheroid on day 15 shown in
Fig. 2a, that the core of the STEM harbors a mixed
population of live (green) and dead cells (red), with a
higher population of live cells in the periphery. The
localization of dead cells within the tumor core may be
attributed to restricted nutrient transport into the core
as is also seen in vivo [1, 3] and also in other multicellu-
lar spheroid systems [36]. The hypoxic nature of the
core was confirmed by staining with Hypoxyprobe, a
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probe for visualization of hypoxia. It was observed that
the hypoxic regions were mostly present in the core (r)
and intermediate zone (r’-r) of the spheroids and coincide
with the populations of dead cells, while cells in the per-
iphery (r΄΄-r΄), frequently referred to as the proliferating
zone, showed fewer signs of exposure to hypoxia (Fig. 2b).
Characterization of core of STEMs
Generally, when two cell populations are intermixed in
3-D culture, one of the cell population tends to envelope
the other and forms a “sphere-in-sphere” organization
[37]. However, in a tumor environment, various pheno-
typically distinct cells coexist in close proximity to one
another and often lose some of the organizational
restrictions, and exert strong paracrine effects. Using
endothelial and epithelial cells expressing eGFP and
eRFP, respectively, the organization of the three cell
types within the STEMs at day 15 was visualized and
qualitatively assessed (Fig. 2c). It is evident that, while
the distribution of epithelial and endothelial cells were
heterogeneous, MSCs on the other hand were quite homo-
geneously distributed throughout the spheroid cross-
section. However, no “sphere-in-sphere” organization was
observed. Remarkably, the core of the spheroid was domi-
nated by MSCs and strikingly devoid of any epithelial cells.
However, an even more unexpected finding was that the
hypoxic core, in addition to MSCs, harbored a small popu-
lation of viable endothelial cells as discussed later, which
Fig. 2 a Confocal image of the synthetic tumor microenvironment mimic (STEM) spheroid after staining for live and dead cells (Green color
represents calcein AM staining indicating live cells, and red represents ethidium homodimer staining indicating dead cells) (Scale bar – 200 μm).
b (i) Immunostaining of STEM at the end of day 15 for hypoxia marker pimonidazole. Hypoxia was confirmed by antibody binding (pink color)
which is prominent in the interior of the STEM. The nuclei were counter-stained with DAPI. (ii) Scoring of proliferation and hypoxia within various
regions of the STEM. The scoring was adapted from Mikhail et al.[25]. c Fluorescent micrographs of STEMs generated using turbo GFP expressing
human pulmonary microvascular endothelial cells (HPMECs), turbo RFP expressing A549, and MSCs, which turbo GFP and turbo RFP negative cells,
i.e. only DAPI positive. Cell nuclei were stained blue using DAPI nuclear stain. DAPI positive, GFP negative and RFP negative cells in the merged
image represent MSC populations (represented by blue color) (Scale bar 100 μm)
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appear closely associated with MSCs. It is well known that
MSCs play a crucial role as support cells for endothelial
cells [15], and it has been reported that, apoptosis of endo-
thelial cells is inhibited under hypoxic conditions [38].
Therefore, it appears that hypoxia and MSCs might have a
synergestic effect on EC survival and such interactions
might be promoted in STEMs, however this aspect re-
quires further investigation.
Immunohistochemical characterization of STEMs
environment for fibrillar fibronectin (FN), and intermediate
filament (IF) proteins cytokeratin-18 (CK18) and vimentin
FN plays a very important role in organization of cells,
cell-cell and cell-matrix interactions [39, 40], and has
been implicated in the progression of human lung
adenocarcinoma [41]. Dysregulation in FN expression is
also thought to contribute to enhanced malignancy [42],
suppression of apoptosis [43], and resistance to chemo-
therapeutics [43, 44]. STEM sections on day 15 showed
markedly intense and more uniform staining for FN than
observed for cells in triculture in 2-D (Fig. 3a). The nega-
tive controls showed no staining, indicating the specificity
of the antibody to FN (Additional file 1: Figure S1). This is
rather surprising considering the cellular heterogeneity
within the STEMs, however such robust expression of FN
in 3-D cultures is expected as cells experience more cell-
cell contact and paracrine effects in a 3-D environment
versus 2-D cultures.
In addition to FN, IF proteins such as CK-18, a marker
for epithelial phenotype, and vimentin, an IF protein
commonly associated with epithelial–mesenchymal tran-
sition (EMT) [1], and also expressed by MSCs, have
been shown to be good indicators of epithelial cancer
progression [45, 46] and invasiveness [47]. In cervical
cancer, an increase in CK18 expression has been associ-
ated with disease progression and resistance to cytokine
induced apoptosis [48], and in cancers of epithelial ori-
gin, upregulation of vimentin is strongly associated with
a high degree of tumor growth, invasion, and decreased
prognosis [49]. In contrast to FN, staining for both CK
18 and vimentin was both spatially discrete and intense
(Fig. 3b and c), and negative controls showed no stain-
ing, indicating specificity of the antibodies to the protein
of interest (Additional file 1: Figure S1). Since only A549
cells express CK18 (Additional file 2: Figure S2), the for-
mation of discrete foci of intense CK18 (and vimentin
expression) staining might be indicative of either epithe-
lial cells demonstrating migratory/invasive phenotype or
organizing to form 3-D structures. Although an EMT
marker, vimentin is inherently expressed by MSCs. Since
MSCs are uniformly distributed within the STEMs at
day 15 (Fig. 2c), the appearance of regions with strong
expression of vimentin, which we refer to as vimentin
“hot spots”, might originate from MSC populations in
close association with A549s, or possibly A549s under-
going EMT like transformation. Nevertheless, while this
reasoning needs further elucidation, the presence of
vimentin “hot spots”, is one of the unique characteristics
of the epithelial/endothelial/MSC STEM environment.
CD31 staining of STEMs
The presence of endothelial cells in close proximity to
MSCs in the core of the STEMs is an intriguing finding
that also represents one of the unique characteristics of
the epithelial/endothelial/MSC STEM environment. Since
it is well established that lung vascular endothelial cells
express CD31 [50], staining for CD31 was undertaken in
order to ascertain if these eGFP+ cells were indeed of
endothelial origin. Although, very few CD31+ cells were in
Fig. 3 Immunohistochemical staining of STEM cryo-sections at day
15 (left panel): (a) fibronectin, (b) CK-18, (c) vimentin, and (d) CD-31,
and (right panel) 2-D tri-culture controls. A549 population indicated
by red arrowhead, HPMEC population indicated by green arrowhead,
and MSC population indicated by blue arrowhead. Scale bar for low
magnification images – 100 μm, scale bar for inset – 50 μm. Negative
controls are shown in Additional file 1: Figure S1
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general observed within the STEMs (Fig. 3d); however,
consistent with the observations using labeled cells
(Fig. 2c), the primary concentration of CD31+ cells was in
the vicinity of the hypoxic STEM core. Mislabelling of cell
populations could be ruled out as the specificity of CD31
antibody to ECs was verified using a negative control
(Additional file 1: Figure S1). Thus, it appears that MSC-
endothelial cell interactions are promoted within the
STEMs, and more prominently in hypoxic regions. Such
interactions are plausible considering that in the past few
years compelling evidence have emerged for a crosstalk
and interdependency between ECs and MSCs [51] and
cancer cells [52]. Furthermore, in angiogenesis, it is well
known that pericytes, which are MSC-like cells, act as
physical scaffolds to support vascular cells and support
angiogenesis [15]. It is also known that mural cells found
within vasculature can give rise to multi-lineage MSCs
[15]. Since it has also been shown the ECs arising from
gliomas undergo the same genomic alteration as the
tumor cells [53], taken in sum these observation allude to
a more complex interplay between MSCs, tumor cells and
ECs. Therefore, our finding that ECs can survive within
the oxygen depleted environment of the STEM core is im-
portant for two reasons as: (1) it suggests that the hypoxic
regions within tumors might, in addition to CSCs, harbor
a genetically different sub-population of ECs and (2) if
such EC populations are identified in vivo, the STEM plat-
form provides a means to investigate changes to endothe-
lial cell phenotype ex vivo in a controlled setting.
Characterization of drug resistance markers expressed
by STEMs and response of STEMs to paclitaxel and
gemcitabine
The presence of a heterogeneous population of cells with
varying metabolic needs, when coupled with nutrient dif-
fusion limitations, can promote a stress response in cells.
It is known that hypoxia and reactive oxygen species
(ROS) production are closely related and can influence
several aspects of tumor biology like angiogenesis and
pathological alterations in various metabolic pathways
[54]. It has been reported that elevated ROS levels in can-
cer cells can influence their proliferation, survival, resist-
ance to chemotherapy, metastatic potential, and promote
stemness [55, 56]. ROS levels in STEM cultures were
compared to 2-D tri-cultures and it was observed that the
production of ROS in the STEM environment was dem-
onstrably higher (4–5 fold greater) as compared to cells
grown on 2-D tissue culture polystyrene (TCPS) (Fig. 4a).
Cells within a tumor environment, in addition to experi-
encing higher oxidative stress, also show changes in efflux
transporters. One family of efflux transporters whose up-
regulation has been linked to drug resistance are the ATP-
Fig. 4 (a) Quantification of reactive oxygen species (arbitrary units) induction in synthetic tumor microenvironment mimic (STEM) (at the end of
day 15) and 2-D tissue culture polystyrene (TCPS) (at the end of 24 h) normalized to cell number. (** indicates significance (p < 0.01) between STEM
and 2-D TCPS, n = 3). (b) ABC-B1 mRNA expression levels in STEM (at the end of day 15), and 2-D TCPS as assessed by real-time PCR. Expressions are
normalized to 18 s rRNA and 2-D TCPS (* indicates significance (p < 0.05) between 2-D TCPS and STEM) and (c & d), Cell viability (normalized
with respect to untreated control) of STEM and cells grown on 2-D TCPS following exposure to paclitaxel and gemcitabine at the end of 48 h
of treatment ((* indicates (p < 0.05) between STEM and 2-D TCPS, 10 nM paclitaxel and (*** indicates (p < 0.005) between STEM and 2-D TCPS,
100 μm, gemcitabine (n = 3))
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cassette binding proteins (ABC transporters) [57]. PCR
analysis revealed that the ABC-B1 mRNA expression was
elevated in STEMs and was almost 3-fold greater when
compared to tri-cultures of A549/HPMEC/MSCs in 2-D
(Fig. 4b). This finding prompted us to investigate the vul-
nerability of STEMs to dose escalation of two common
chemotherapeutic agents, paclitaxel and gemcitabine.
STEMs and 2-D tri-cultures were exposed to escalating
doses of paclitaxel (1, 10, 100, and 1000 nM) and gemcita-
bine (1, 10, 30, and 100 μM), and the cell viability was
assessed by MTT 48 h after continuous exposure (Fig. 4c
and d). In the case of paclitaxel, at a low dose of 1 nM, no
statistically significant difference in cell survival was ob-
served between STEMs and control 2-D tri-cultures.
However, at a dose of 10 nM a statistically significant (p =
0.0152), increase in cell survival was observed in the
STEMs versus 2-D tri-cultures. Further dose escalation to
1000 nM did not result in any significant differences in
cell survival in STEMs versus 2-D. In the case of gemcita-
bine, there were no statistically significant differences in
cell survival until a dose of 30 μM. Above this dose, a con-
sistently 10 % higher viability was observed in STEMs ver-
sus 2-D. This difference, although modest, was statistically
significant with p value of 0.0039 for 100 μM. Neverthe-
less, the absence of much larger differences in cell survival
in STEMs versus 2-D cultures is an unexpected finding in
view of the elevated ROS levels and upregulation in ABC-
B1. One possible explanation could be that MSCs confer
some protective effect on the cells. However, another
likely explanation is that multiple drug resistance (MDR)
requires additional inputs, perhaps in the form of immu-
nomodulation and soluble signals. This aspect of the
STEM characteristic therefore, needs further refinement.
Conclusions
Synthetic tumor microenvironment mimics, STEMs,
composed of human lung epithelial, human lung endo-
thelial, and human marrow-derived mesenchymal cells,
were prepared using the hanging drop method, and
characterized for their cellular and matrix characteristics
(morphology, cell composition, and FN, CK18, vimentin,
and CD31 expression), ROS production, and expression
of drug resistance marker ABC-B1. After 15 days, STEMs
showed many interesting characteristics including a hyp-
oxic core that was devoid of epithelial cells but dominated
by MSCs and a small but viable population of endothelial
cells appear to be closely associated with MSCs in the
hypoxic core. Immunohistochemistry revealed that, while
FN expression was strong throughout, discrete regions
that were positive for CK-18 and vimentin were present.
Additionally, cells within STEMs showed high levels of
ROS and upregulation of drug-resistance phenotype asso-
ciated marker such as ABC-B1. In spite of the upregula-
tion of marker associated with MDR, no appreciable
differences in cell viability were observed between STEMs
and 2-D tri-cultures in response to dose escalation of pac-
litaxel and gemcitabine. This unexpected finding suggests
that the MDR phenotype might additionally require im-
mune modulation and soluble signals. Nevertheless, the
epithelial/endothelial/MSC 3-D culture model described
herein bears many unique traits associated with cancer en-
vironments, and presents a useful platform for under-
standing tumor biology and drug screening.
Additional files
Additional file 1: Figure S1. Immunohistochemical staining showing
negative controls in 3-D and 2-D Triculture (Scale bar: 100 μm). (DOCX 343 kb)
Additional file 2: Figure S2. Immunohistochemical staining against
cytokeratin 18 in A549, human pulmonary microvascular endothelial cells
(HPMEC), mesenchymal stem cells (MSCs) and 2-D Triculture (Scale bar:
100 μm for low magnification and 50 μm for high magnification images).
(DOCX 1749 kb)
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